IGF1 and atypical Rett syndrome: On the other hand, Trofinetide, a small synthetic analog tripeptide derivative of IGF-1, was recently approved in the United States for the treatment of a rare childhood neurodevelopmental disorder, Rett syndrome, where administration is associated with significant symptom improvements39.